Cetera Investment Advisers Has $1.87 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Cetera Investment Advisers lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,317 shares of the biopharmaceutical company’s stock after selling 4,882 shares during the period. Cetera Investment Advisers’ holdings in TG Therapeutics were worth $1,866,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Soleus Capital Management L.P. grew its stake in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after purchasing an additional 146,702 shares in the last quarter. Northern Trust Corp grew its stake in TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after purchasing an additional 120,785 shares in the last quarter. Invesco Ltd. grew its stake in TG Therapeutics by 1.2% in the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock valued at $27,985,000 after purchasing an additional 10,989 shares in the last quarter. Principal Financial Group Inc. grew its stake in TG Therapeutics by 1.3% in the first quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company’s stock valued at $33,161,000 after purchasing an additional 10,827 shares in the last quarter. Finally, Braun Stacey Associates Inc. grew its stake in TG Therapeutics by 13.5% in the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company’s stock valued at $19,819,000 after purchasing an additional 59,845 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Activity

In other news, Director Yann Echelard sold 10,000 shares of the company’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 10.64% of the company’s stock.

TG Therapeutics Stock Performance

TGTX opened at $26.71 on Friday. The company has a market cap of $4.24 billion, a PE ratio of 72.19 and a beta of 1.95. The stock has a 50-day moving average of $36.10 and a 200-day moving average of $35.95. TG Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $46.48. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a return on equity of 27.83% and a net margin of 13.31%. The business’s revenue was up 92.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.04 EPS. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.25.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.